Challenges and Considerations in Modern Adjuvant Therapy Trials in Renal Cell Carcinoma: A Call to Power.
editorial · Level V
Where this comes from
- Record sourced from PubMed, PMID 39472204.
- Also identified by DOI 10.1016/j.eururo.2024.10.020.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Identification of effective adjuvant therapies for renal cell carcinoma remains challenging despite the development of immune checkpoint inhibitors. Enhancement of the design of trials of adjuvant therapy by focusing on populations with the highest risk and increasing the sample size is essential for reliable assessments of therapeutic efficacy.
Medical subject headings
- Carcinoma, Renal Cell
- Clinical Trials as Topic
- Kidney Neoplasms